Ghrelin Treatment of Cachectic Patients with Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pulmonary cachexia is common in advanced chronic obstructive pulmonary disease (COPD), culminating in exercise intolerance and a poor prognosis. Ghrelin is a novel growth hormone (GH)-releasing peptide with GH-independent effects. The efficacy and safety of adding ghrelin to pulmonary rehabilitation (PR) in cachectic COPD patients were investigated. METHODOLOGY/PRINCIPAL FINDINGS: In a multicenter, randomized, double-blind, placebo-controlled trial, 33 cachectic COPD patients were randomly assigned PR with intravenous ghrelin (2 µg/kg) or placebo twice daily for 3 weeks in hospital. The primary outcomes were changes in 6-min walk distance (6-MWD) and the St. George Respiratory Questionnaire (SGRQ) score. Secondary outcomes included changes in the Medical Research Council (MRC) scale, and respiratory muscle strength. At pre-treatment, serum GH levels were increased from baseline levels by a single dose of ghrelin (mean change, +46.5 ng/ml; between-group p<0.0001), the effect of which continued during the 3-week treatment. In the ghrelin group, the mean change from pre-treatment in 6-MWD was improved at Week 3 (+40 m, within-group p = 0.033) and was maintained at Week 7 (+47 m, within-group p = 0.017), although the difference between ghrelin and placebo was not significant. At Week 7, the mean changes in SGRQ symptoms (between-group p = 0.026), in MRC (between-group p = 0.030), and in maximal expiratory pressure (MEP; between-group p = 0.015) were better in the ghrelin group than in the placebo group. Additionally, repeated-measures analysis of variance (ANOVA) indicated significant time course effects of ghrelin versus placebo in SGRQ symptoms (p = 0.049) and MEP (p = 0.021). Ghrelin treatment was well tolerated. CONCLUSIONS/SIGNIFICANCE: In cachectic COPD patients, with the safety profile, ghrelin administration provided improvements in symptoms and respiratory strength, despite the lack of a significant between-group difference in 6-MWD. TRIAL REGISTRATION: UMIN Clinical Trial Registry C000000061.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479 · cited 1×
“[7].”
Self-citationGhrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949
A role for ghrelin in the central regulation of feeding
Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., & Matsukura, S. (2001) · Nature · doi:10.1038/35051587 · Cited by 3,443 · cited 2×
“Meanwhile, previous studies showed that ghrelin administration induced a positive energy balance and weight gain [8], increased food intake [9,13], and decreased sympathetic nervous activity [10,11,13].”
BackgroundSelf-citationJones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035 · cited 14×
“Outcome Measure Efficacy: The primary outcomes were changes in 6-min walk distance (6-MWD) and the score evaluated using the St. George Respiratory Questionnaire (SGRQ) [14].”
InfluentialGrowth Hormone Replacement in Healthy Older Men Improves Body Composition but Not Functional Ability
Papadakis, M. A., Grady, D., Black, D., Tierney, M. J., Gooding, G. A. W., Schambelan, M., & Grunfeld, C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-8-199604150-00002 · Cited by 474
Blackman, M. R. (2002) · JAMA · doi:10.1001/jama.288.18.2282 · Cited by 455
Systematic review: the safety and efficacy of growth hormone in the healthy elderly
Liu, H., Bravata, D. M., Olkin, I., Nayak, S., Roberts, B., Garber, A. M., & Hoffman, A. R. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00005 · Cited by 370 · cited 2×
“Similarly, 4 weeks after treatment, the effect of ghrelin on respiratory muscle strength was confirmed, though it has been reported that GH alone does not increase strength in healthy elderly [22,23,24].”
BackgroundResultAnawalt, B. D., & Merriam, G. R. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70206-1 · Cited by 93
Cited by
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Müller, T. D., Nogueiras, R., Andermann, M. L., Andrews, Z. B., Anker, S. D., Argente, J., Batterham, R. L., Benoit, S. C., Bowers, C. Y., Broglio, F., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.03.005 · Cited by 1,034
Self-citationThe Homeostatic Force of Ghrelin
Yanagi, S., Sato, T., Kangawa, K., & Nakazato, M. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.008 · Cited by 321
Self-citationGhrelin: much more than a hunger hormone
Pradhan, G., Samson, S. L., & Sun, Y. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328365b9be · Cited by 288
A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease
Marty, E., Liu, Y., Samuel, A., Or, O., & Lane, J. (2017) · Bone · doi:10.1016/j.bone.2017.09.008 · Cited by 288
Metadata
- Authors
- Miki, K., Maekura, R., Nagaya, N., Nakazato, M., Kimura, H., Murakami, S., Ohnishi, S., Hiraga, T., Miki, M., Kitada, S., Yoshimura, K., Tateishi, Y., Arimura, Y., Matsumoto, N., Yoshikawa, M., Yamahara, K., & Kangawa, K.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-05-01
- Volume
- 7
- Issue
- 5
- Pages
- e35708
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2005864976
- Cited by
- 123
- References
- 8
- FWCI
- 12.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ghrelin Treatment of Cachectic Patients with Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1371/journal.pone.0035708
- The paper
- Miki, K., Maekura, R., Nagaya, N., Nakazato, M., Kimura, H., Murakami, S., Ohnishi, S., Hiraga, T., Miki, M., Kitada, S., Yoshimura, K., Tateishi, Y., Arimura, Y., Matsumoto, N., Yoshikawa, M., Yamahara, K., & Kangawa, K. (2012). Ghrelin Treatment of Cachectic Patients with Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PLoS ONE. https://doi.org/10.1371/journal.pone.0035708
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.